|Bid||111.19 x 1100|
|Ask||111.20 x 800|
|Day's Range||106.51 - 120.51|
|52 Week Range||53.21 - 133.96|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 29, 2017 - Sep 4, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||166.41|
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will host an R&D Day for the investment community on Wednesday, June 26, 2019 in New York City. The event will feature an update on the company’s three endocrinology rare disease programs, including detailed data on the TransCon hGH phase 3 heiGHt and fliGHt Trials, updates on the TransCon PTH and TransCon CNP programs, an introduction to the commercial organization, and an introduction of the oncology vision, strategic goals and potential product candidates, with presentations from an outside oncology expert and Ascendis senior management. If you are a member of the investment community and would like to attend, please send an email to email@example.com to receive additional information.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature.
NEW YORK, NY / ACCESSWIRE / May 30, 2019 / Ascendis Pharma A/S (NASDAQ: ASND ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 30, 2019 at 4:30 PM Eastern ...
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced preliminary results from the phase 3 fliGHt Trial of TransCon Growth Hormone (hGH). The results indicated treatment with TransCon hGH was safe and well-tolerated in subjects with pediatric growth hormone deficiency (GHD) who were previously treated with commercially-available daily growth hormone therapies.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Thursday, May 30, 2019 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2019 financial results and provide a business update. A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in an upcoming investor conference. A live webcast of the event will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
Sohn Conference is my favorite hedge fund event. I haven't missed an event since 2013. This doesn't mean that every stock pitched at the conference is a great investment opportunity and will beat its benchmark. A few weeks ago we took a look at the performance of the stocks pitched at the 2018 Sohn Conference […]
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ascend...
Is Ascendis Pharma A/S (NASDAQ:ASND) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Glenview Capital Management is a New York City-based hedge fund, that was launched 18 years ago by Larry Robbins, who previously worked as a trader for billionaire Leon Cooperman’s Omega Advisors. The fund posted return of 301% after fees and expenses for the first decade of its existence, even though 2008 posed too many difficulties […]
COPENHAGEN, Denmark, April 24, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet.
Harvest Capital Strategies is a San Francisco-based hedge fund that mainly focuses on private equity and venture capital, middle-market lending and on equity hedge funds. It was founded back in 1999, and it operates as a subsidiary of JMP Group Inc. Joseph Jolson, the fund’s CEO, co-founded JMP Group and is its CEO and the […]
Read the beginning of this article here. Nathaniel August recommended a position in Peabody Energy (NYSE:BTU) which “is the largest and least expensive way to participate in the coal market” according to this fund manager. Unfortunately the stock lost more than 26% since August’s recommendation. David Einhorn recommended a short position in Assured Guaranty (NYSE:AGO) due […]
It has been almost a year since the last annual Sohn Conference held in New York, and we thought it would be interesting to take a look at how some of the stock pitches presented there have performed since. Today, we are going to take a look at Light Street’s Glen Kacher’s best idea from […]
Nathaniel August’s Mangrove Partners is known for outperforming the market very often; in the first three years since its launching (2010), the fund brought an astonishing return of 44% annually. It continued with its strong performance in the next year, delivering 26.6%. In spite of losing around 1.9% in 2015, the fund compensated for it […]
Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning 15.5%. Just for the comparison, an average activist hedge fund reported a loss of 11% in the same period, and the S&P 500 lost 4.4%. Even over the last three years, the fund […]
– Rare disease endocrinology pipeline continues to advance, with significant 2019 milestones anticipated – – Phase 3 heiGHt Trial results showcase potential of TransCon™.
NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ASND ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 3, 2019 ...
COPENHAGEN, Denmark, March 27, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet.
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced a study evaluating impact of hypoparathyroidism (HP) on patients in a poster at the Endocrine Society’s annual meeting, ENDO 2019, in New Orleans. The study found that, despite treatment with current therapies, 100 percent of patients experienced physical impact, psychological impact, and interference with daily life, reflecting a substantial illness burden from HP. “I have lived with HP for over 25 years and have personally experienced how this debilitating disease affects all areas of life - physical, emotional and social,” said Deb Murphy, President of the HypoPARAthyroidism Association, Inc. “This study highlights that currently available therapies are still not enough.